{
    "2021-06-18": [
        [
            {
                "time": "",
                "original_text": "医药生物行业2021年下半年投资策略：短期有扰动 长期发展趋势向好",
                "features": {
                    "keywords": [
                        "医药生物",
                        "投资策略",
                        "短期扰动",
                        "长期趋势"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【万联医药 | 半年度策略】分化加剧，把握结构性机会",
                "features": {
                    "keywords": [
                        "万联医药",
                        "半年度策略",
                        "分化加剧",
                        "结构性机会"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "华西证券：盈康生命（300143.SZ）持续推进肿瘤医疗服务板块“1+N”全国布局，维持“买入”评级",
                "features": {
                    "keywords": [
                        "华西证券",
                        "盈康生命",
                        "肿瘤医疗",
                        "1+N布局",
                        "买入评级"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "北向资金减持榜单：24股减持市值超亿元 减持股份",
                "features": {
                    "keywords": [
                        "北向资金",
                        "减持",
                        "市值超亿"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "上新中国版“纳指”！这个指数你必须了解一下",
                "features": {
                    "keywords": [
                        "中国版纳指",
                        "指数"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "投资科技创新再增新渠道 首批双创50ETF正式获批下周发售",
                "features": {
                    "keywords": [
                        "科技创新",
                        "双创50ETF",
                        "新渠道",
                        "获批"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业投资策略报告：分化加剧 把握结构性机会",
                "features": {
                    "keywords": [
                        "医药生物",
                        "投资策略",
                        "分化加剧",
                        "结构性机会"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}